PL1613328T3 - Zastosowanie pochodnych karbamezepiny do leczenia stanów pobudzenia u pacjentów z otępieniem - Google Patents
Zastosowanie pochodnych karbamezepiny do leczenia stanów pobudzenia u pacjentów z otępieniemInfo
- Publication number
- PL1613328T3 PL1613328T3 PL04724599T PL04724599T PL1613328T3 PL 1613328 T3 PL1613328 T3 PL 1613328T3 PL 04724599 T PL04724599 T PL 04724599T PL 04724599 T PL04724599 T PL 04724599T PL 1613328 T3 PL1613328 T3 PL 1613328T3
- Authority
- PL
- Poland
- Prior art keywords
- agitation
- treatment
- dementia patients
- compound
- formula
- Prior art date
Links
- 206010001497 Agitation Diseases 0.000 title abstract 3
- 238000013019 agitation Methods 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title abstract 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 abstract 2
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 abstract 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- -1 calcium antagonists Substances 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003642 nicergoline Drugs 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004986 pyritinol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960002726 vincamine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Plant Substances (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45933803P | 2003-04-01 | 2003-04-01 | |
| EP04724599A EP1613328B8 (en) | 2003-04-01 | 2004-03-31 | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| PCT/EP2004/003418 WO2004087166A1 (en) | 2003-04-01 | 2004-03-31 | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1613328T3 true PL1613328T3 (pl) | 2009-08-31 |
Family
ID=33131880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04724599T PL1613328T3 (pl) | 2003-04-01 | 2004-03-31 | Zastosowanie pochodnych karbamezepiny do leczenia stanów pobudzenia u pacjentów z otępieniem |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20070066593A1 (pl) |
| EP (1) | EP1613328B8 (pl) |
| JP (1) | JP2006522050A (pl) |
| KR (1) | KR20050121236A (pl) |
| CN (1) | CN1767833A (pl) |
| AT (1) | ATE425756T1 (pl) |
| AU (1) | AU2004226805B2 (pl) |
| BR (1) | BRPI0408956A (pl) |
| CA (1) | CA2521371A1 (pl) |
| DE (1) | DE602004020060D1 (pl) |
| ES (1) | ES2323270T3 (pl) |
| HR (1) | HRP20050872A2 (pl) |
| IS (1) | IS8096A (pl) |
| MA (1) | MA27638A1 (pl) |
| MX (1) | MXPA05010608A (pl) |
| NO (1) | NO20054994L (pl) |
| NZ (1) | NZ542554A (pl) |
| PL (1) | PL1613328T3 (pl) |
| PT (1) | PT1613328E (pl) |
| RU (1) | RU2351338C2 (pl) |
| TN (1) | TNSN05247A1 (pl) |
| TW (1) | TW200501962A (pl) |
| WO (1) | WO2004087166A1 (pl) |
| ZA (1) | ZA200507439B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US20110251172A1 (en) * | 2008-08-13 | 2011-10-13 | Rivkin Alexey A | Purine derivatives for treatment of alzheimer's disease |
| CN102183659B (zh) * | 2011-03-02 | 2014-07-02 | 广州金域医学检验中心有限公司 | 一种卡马西平检测方法 |
| CN102180965B (zh) * | 2011-03-02 | 2014-01-01 | 广州金域医学检验中心有限公司 | 卡马西平免疫原、抗卡马西平特异性抗体、检测试剂及检测试剂盒 |
| RU2504367C1 (ru) * | 2012-06-05 | 2014-01-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации | Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) * | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US3637661A (en) * | 1970-03-04 | 1972-01-25 | Ciba Geigy Corp | 10-hydroxy-10 11-dihydro-dibenzazepine derivative |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| JP3057471B2 (ja) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンｉｉ介在性諸疾患の予防または治療剤 |
| PT101732B (pt) * | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| US5736647A (en) * | 1995-08-07 | 1998-04-07 | Oval Corporation | Vortex flow meter detector and vortex flow meter |
| IL142588A0 (en) * | 1998-10-16 | 2002-03-10 | Janssen Pharmaceutica Nv | Therapy for improving cognition |
| EP1246632A4 (en) * | 1999-12-30 | 2004-08-18 | Proteotech Inc | CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER |
| GB0113663D0 (en) * | 2001-06-05 | 2001-07-25 | Novartis Ag | Use of organic compounds |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
-
2004
- 2004-03-29 TW TW093108532A patent/TW200501962A/zh unknown
- 2004-03-31 PL PL04724599T patent/PL1613328T3/pl unknown
- 2004-03-31 US US10/550,380 patent/US20070066593A1/en not_active Abandoned
- 2004-03-31 CN CNA2004800084961A patent/CN1767833A/zh active Pending
- 2004-03-31 RU RU2005133478/15A patent/RU2351338C2/ru not_active IP Right Cessation
- 2004-03-31 EP EP04724599A patent/EP1613328B8/en not_active Expired - Lifetime
- 2004-03-31 MX MXPA05010608A patent/MXPA05010608A/es active IP Right Grant
- 2004-03-31 WO PCT/EP2004/003418 patent/WO2004087166A1/en not_active Ceased
- 2004-03-31 AU AU2004226805A patent/AU2004226805B2/en not_active Ceased
- 2004-03-31 NZ NZ542554A patent/NZ542554A/en unknown
- 2004-03-31 KR KR1020057018720A patent/KR20050121236A/ko not_active Ceased
- 2004-03-31 BR BRPI0408956-1A patent/BRPI0408956A/pt not_active IP Right Cessation
- 2004-03-31 ES ES04724599T patent/ES2323270T3/es not_active Expired - Lifetime
- 2004-03-31 DE DE602004020060T patent/DE602004020060D1/de not_active Expired - Fee Related
- 2004-03-31 JP JP2006504935A patent/JP2006522050A/ja active Pending
- 2004-03-31 PT PT04724599T patent/PT1613328E/pt unknown
- 2004-03-31 AT AT04724599T patent/ATE425756T1/de not_active IP Right Cessation
- 2004-03-31 HR HR20050872A patent/HRP20050872A2/xx not_active Application Discontinuation
- 2004-03-31 CA CA002521371A patent/CA2521371A1/en not_active Abandoned
-
2005
- 2005-09-15 ZA ZA200507439A patent/ZA200507439B/en unknown
- 2005-09-30 MA MA28522A patent/MA27638A1/fr unknown
- 2005-09-30 TN TNP2005000247A patent/TNSN05247A1/en unknown
- 2005-10-26 NO NO20054994A patent/NO20054994L/no not_active Application Discontinuation
- 2005-10-27 IS IS8096A patent/IS8096A/is unknown
-
2009
- 2009-04-07 US US12/419,651 patent/US20090192142A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054994L (no) | 2005-10-26 |
| ATE425756T1 (de) | 2009-04-15 |
| NZ542554A (en) | 2008-10-31 |
| EP1613328B1 (en) | 2009-03-18 |
| IS8096A (is) | 2005-10-27 |
| EP1613328A1 (en) | 2006-01-11 |
| US20090192142A1 (en) | 2009-07-30 |
| EP1613328B8 (en) | 2009-06-10 |
| CN1767833A (zh) | 2006-05-03 |
| WO2004087166A1 (en) | 2004-10-14 |
| PT1613328E (pt) | 2009-06-15 |
| ZA200507439B (en) | 2007-06-27 |
| TW200501962A (en) | 2005-01-16 |
| KR20050121236A (ko) | 2005-12-26 |
| CA2521371A1 (en) | 2004-10-14 |
| AU2004226805B2 (en) | 2008-03-06 |
| US20070066593A1 (en) | 2007-03-22 |
| BRPI0408956A (pt) | 2006-04-04 |
| DE602004020060D1 (de) | 2009-04-30 |
| TNSN05247A1 (en) | 2007-06-11 |
| RU2351338C2 (ru) | 2009-04-10 |
| RU2005133478A (ru) | 2007-06-10 |
| MA27638A1 (fr) | 2005-11-01 |
| JP2006522050A (ja) | 2006-09-28 |
| HK1090543A1 (en) | 2006-12-29 |
| ES2323270T3 (es) | 2009-07-10 |
| HRP20050872A2 (en) | 2006-12-31 |
| MXPA05010608A (es) | 2005-11-23 |
| AU2004226805A1 (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138352A (en) | Benzothiazole derivatives | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| BR0317600A (pt) | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina | |
| WO2007143523A8 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| TR200102782T2 (tr) | Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| PL1682528T3 (pl) | Pochodne benzo[b][1,4]dioksepiny | |
| UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| NO20032261L (no) | Medisinske preparater | |
| MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| WO2006038006A3 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
| TW200519101A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| EP1613328B8 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| ZA961069B (en) | Heterocyclic derivatives | |
| EA200601687A1 (ru) | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 | |
| SE0002729D0 (sv) | Novel compound form | |
| DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |